Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Tennessee Adstiladrin Prior Auth | OpenPayer
    Ask Trek AI about this page
    DraftBlue Cross Blue Shield - TennesseePolicy ID_CHS_57112026_1126

    Nadofaragene firadenovec-vncg (Adstiladrin) Coverage Criteria

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_57112026_1126 alerts

    Get alerted when Policy ID_CHS_57112026_1126 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Adstiladrin in adult members with eligible high-risk, BCG-unresponsive non-muscle invasive bladder cancer. Coverage requires applicable clinical criteria and supporting documentation; other indications are not medically necessary.

    Policy Summary
    PayerBlue Cross Blue Shield - Tennessee
    PolicyNadofaragene firadenovec-vncg (Adstiladrin) Coverage Criteria
    Policy CodePolicy ID_CHS_57112026_1126
    Change TypeNo material change
    Effective DateJan 30, 2027
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing the applicable bladder-cancer diagnosis, BCG nonresponse, and satisfaction of all coverage criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial authorization period
    12 monthsContinuation authorization period
    3Required initial clinical criteria
    BCG-unresponsive NMIBCCore disease requirement

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Not medically necessaryOther indications

    Coverage Criteria

    Bladder cancer initial therapy

    Covered when all of the following are met:

    Initial therapy criteria

    • Disease presentation

      • Eligible NMIBC presentation: The member has non-muscle invasive bladder cancer with carcinoma in situ or Ta/T1 papillary tumors without carcinoma in situ
    • Disease risk and treatment response

      • The disease is high-risk and BCG-unresponsive

    Continuation therapy

    Covered when both continuation conditions are met:

    Continuation therapy criteria

    • Eligible indication: The member is requesting reauthorization for an indication listed in the coverage criteria section
    • Response and tolerability: There is no evidence of unacceptable toxicity or disease recurrence while on the current regimen

    Indications other than the FDA-approved indication and the listed compendial use are considered experimental/investigational and are not medically necessary.

    Nadofaragene firadenovec-vncg is not medically necessary for indications outside eligible non-muscle invasive bladder cancer presentations, including the specified FDA-approved use and the compendial use of disease without carcinoma in situ.

    Provider Actions and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Adstiladrin® treatment of bladder cancer. Submit the required diagnosis, documentation that the disease is BCG-unresponsive, and supporting clinical records demonstrating that coverage criteria are met.

    • Non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) or Ta/T1 papillary tumors without CIS.
    • High-risk disease.
    • BCG-unresponsive disease.
    • Authorization may be granted for 12 months when all criteria are met.
    Documentation Required

    Document BCG Nonresponse

    To initiate prior authorization review, provide chart notes or other medical-record documentation demonstrating that the member's disease has had no response to BCG.

    Clinical Background

    Nadofaragene firadenovec-vncg (Adstiladrin) is covered for selected adults with high-risk, BCG-unresponsive non-muscle invasive bladder cancer. Coverage includes carcinoma in situ with or without papillary tumors and the listed compendial use for non-muscle invasive bladder cancer without carcinoma in situ.

    Initial Therapy Criteria

    Initial authorization

    Authorization of 12 months may be granted when all of the following criteria are met:

    • NMIBC presentation

      • Eligible NMIBC presentation: The member has non-muscle invasive bladder cancer with carcinoma in situ or Ta/T1 papillary tumors without carcinoma in situ
    • Risk and BCG response

      • The disease is high-risk and BCG-unresponsive

    Continuation Authorization Criteria

    Continuation authorization

    Authorization of 12 months may be granted for continued treatment when all of the following are met:

    Continuation therapy

    • Covered indication: The member is requesting reauthorization for an indication listed in the coverage criteria section
    • No unacceptable toxicity or recurrence: There is no evidence of unacceptable toxicity or disease recurrence while on the current regimen
    Policy Summary
    PayerBlue Cross Blue Shield - Tennessee
    PolicyNadofaragene firadenovec-vncg (Adstiladrin) Coverage Criteria
    Policy CodePolicy ID_CHS_57112026_1126
    Change TypeNo material change
    Effective DateJan 30, 2027
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing the applicable bladder-cancer diagnosis, BCG nonresponse, and satisfaction of all coverage criteria.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and Denial RisksClinical BackgroundInitial Therapy CriteriaContinuation Authorization Criteria
    • Submit chart notes or medical-record documentation of no response to BCG with the authorization request.
    Denial Risk

    Unlisted Indication

    Use outside the FDA-approved or listed compendial indications is considered experimental/investigational and not medically necessary.

    • Listed compendial use: non-muscle invasive bladder cancer without carcinoma in situ.
    • All other indications are experimental/investigational and not medically necessary.
    Denial Risk

    Clinical Criteria Not Met

    Authorization may be denied when the clinical criteria are not met, including requirements for the diagnosis, tumor characteristics, disease risk, or BCG response status.

    • The member must have NMIBC with CIS or Ta/T1 papillary tumors without CIS.
    • The disease must be high-risk.
    • The disease must be BCG-unresponsive.
    • All listed criteria must be satisfied for authorization.
    Denial Risk

    Toxicity or Recurrence During Continuation

    Continuation authorization may be denied when unacceptable toxicity or disease recurrence occurs during the current treatment regimen.

    • Reauthorization applies to an indication listed in the coverage criteria.
    • There must be no evidence of unacceptable toxicity while on the current regimen.
    • There must be no evidence of disease recurrence while on the current regimen.
    • Continuation authorization may be granted for 12 months when the criteria are met.